All News
#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP
Janet Pope Janetbirdope ( View Tweet)
Kiltz et al. Greater efficacy of secukinumab in normal BMI than high BMI AS patients. Decremental effect with increasing BMI. @RheumNow #ACR22 Abstr#1495 https://t.co/zwEmQsJmPT https://t.co/nOW2IbTc5t
Richard Conway RichardPAConway ( View Tweet)
Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69
Richard Conway RichardPAConway ( View Tweet)
Torgutalp et al. Higher NSAID intake associated reduced spinal progression in AxSpA esp. r-AxSpA. Cox-2 may have greater effect than other NSAIDs. @RheumNow #ACR22 Abstr#1492 https://t.co/bGH6bBo7AD https://t.co/XBFV410Y2p
Richard Conway RichardPAConway ( View Tweet)
CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow
https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc
Dr. Rachel Tate uptoTate ( View Tweet)
Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x
Richard Conway RichardPAConway ( View Tweet)
Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F
Dr. Rachel Tate uptoTate ( View Tweet)
Lower socioeconomic status (cluster 1) patients:
● older age at the diagnosis (37.9 vs. 32.6)
● longer diagnosis delay (7.8 vs. 6.8 years)
● higher BMI (27.6 vs. 25.9)
● greater structural damage
vs cluster 2
Lopez-Medina C Abs0376 https://t.co/wXOksFGDKl #ACR22 @RheumNow https://t.co/1YVRA6r1sw
Dr. Antoni Chan synovialjoints ( View Tweet)
Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also
➣ more comorbidities
➣ higher prevalence of smoking
➣ worse disease activity
➣ higher use of anti-rheumatic drugs
Ogdie A Abs0402 https://t.co/3E4qAuqgpI #ACR22 @RheumNow https://t.co/AaKxiQXMwx
Dr. Antoni Chan synovialjoints ( View Tweet)
Lifestyle modifications can affect tx response with TNFi in axSpA!
Accdg to this study fr Prof GJones, ✳️Smokers, overwt & obese pts are ⬇️ likely to achieve treatment response to TNFi vs. nonsmokers & normal wt pts
Smoking cessation, wt mgt is key!
#ACR22 @RheumNow ABST#1510 https://t.co/PBFcj6zKVD
sheila RHEUMarampa ( View Tweet)
De Craemer et al. Local vs Central reading of images. Rheumatologists overcall sacroiliitis on both plain films and MRI in ?AxSpA . ? some of this out of a desire to try something to help someone who is suffering @RheumNow #ACR22 Abstr#1255 https://t.co/j89E0sUPmN https://t.co/Ez5ldSSQJl
Richard Conway RichardPAConway ( View Tweet)
HZ risk after each (1 of 3) BNT162b2 mRNA vaccination doses was not increased in PsA and AS patients compared to a similar time period two years prior . The risk of HZ increased with age. Abs 1489 #ACR22 @RheumNow https://t.co/YmcqDNoxya
Dr. Rachel Tate uptoTate ( View Tweet)
Once again, high BMI and smoking associated with substantial decrease in TNFi response for treatment of axSpA.
Easier said than done however. How are you helping pts lose weight or stop smoking?
Abs#1510 @RheumNow #ACR22 https://t.co/ircLkuXhCs
Robert B Chao, MD doctorRBC ( View Tweet)
Gut microbiota of axSpA pts who underwent bDMARD tx for one year more closely resembled controls. Unique enrichment of Collinsella in axSpA patients remained stable across time & tx, suggesting it may be a disease biomarker. Abs 1162 #ACR22 @RheumNow https://t.co/SjwORWp6IU https://t.co/rLlu4jGCfd
Dr. Rachel Tate uptoTate ( View Tweet)
GM-CSF inc'd in active AS pts, particularly in younger ages, and strongly correlates with disease activity, but not with disease duration. TNFi tx does not affect GM-SCF levels, despite improving disease activity. Abs 1156 #ACR22 @RheumNow https://t.co/ndhBGbPsCw
Dr. Rachel Tate uptoTate ( View Tweet)
Nice study on referral strategies for #axSpA in pts w/ chronic LBP by Dr @Nellziade
🔸MASTER strategy-optimal reference strategy: IBP, ✅NSAID response, HLA-B27+ & +SpA family hx
🔸Clinical predictive factors: uveitis, IBP, Pso, enthesitis &🚹
#ACR22 @RheumNow ABST#1512 #ACRBest https://t.co/l6AleXX7Kt
sheila RHEUMarampa ( View Tweet)
Decreased colonic mucus production in HLA-B27 + healthy individuals and axSpA and IBD pts. Abs 1151 #ACR22 @RheumNow https://t.co/CwX4n6PJFy https://t.co/4f1Za0Qhpj
Dr. Rachel Tate uptoTate ( View Tweet)
Biologics to treat gut microbiome dysbiosis??
In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls.
Collinsella remained stable - possible biomarker?
Abs#1162 @RheumNow #ACR22
#ACRBest https://t.co/vmQFJMpNPP
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 1153 at #ACR22 males may have a higher levels of Th17-associated transcription factors. Radiographic progression in men may be mediated by S100 proteins and prostaglandins. @RheumNow https://t.co/mWbsaB8kK8 https://t.co/IkTBZcaqa6
Dr. Rachel Tate uptoTate ( View Tweet)
Inflammation causing HTN in AS?
Abstract #0384 #ACR22 @RheumNow
🫀413 patients followed for median 12 years
🫀14% developed HTN
🫀Baseline disease duration was an independent RF for HTN
🫀ESR > 20 sig. associated with HTN
Catherine Sims, MD DrCassySims ( View Tweet)
